All scaffolds
GLP-1 / incretin agonist series
GLP-1 / incretin2일 전GLP-1 receptor agonist chemotypes from exenatide/liraglutide to semaglutide, dual GIP/GLP-1 tirzepatide, triple agonists, and oral small-molecule orforglipron.
맵 로딩 중…
GLP-1 receptor agonist chemotypes from exenatide/liraglutide to semaglutide, dual GIP/GLP-1 tirzepatide, triple agonists, and oral small-molecule orforglipron.
맵 로딩 중…
약물명 · 2D 구조식 · SMILES · 역할 · 파생 출처 · core 유사도 · 특성(태그·노트)을 맵 위에 텍스트로 요약합니다. 행을 클릭하면 상세가 열립니다.
| 2D | 약물 / 화합물 | 역할 | 구조식 (SMILES) | 파생 출처 | Core 유사 | 특성 |
|---|---|---|---|---|---|---|
| GLP-1 incretin pharmacophoreglp1-incretin-core | Scaffold | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | — | — | GLP-1 · incretin · core · Shared pharmacophore / core scaffold. Anchor for the GLP-1 / incretin agonist series linea… | |
| Dulaglutide (Trulicity)dulaglutide | Drug | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | GLP-1 incretin pharmacophore | 67% | approved · GLP-1 · peptide · weekly · Approved therapeutic. Dulaglutide (Trulicity) in this family map. · CHEMBL2107876 | |
| Exenatide (Byetta / Bydureon)exenatide | Drug | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | GLP-1 incretin pharmacophore | 73% | approved · GLP-1 · peptide · Approved therapeutic. Exenatide (Byetta / Bydureon) in this family map. · CHEMBL1201515 · CID 45588096 | |
| Liraglutide (Victoza / Saxenda)liraglutide | Drug | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | GLP-1 incretin pharmacophore | 72% | approved · GLP-1 · peptide · obesity · Approved therapeutic. Liraglutide (Victoza / Saxenda) in this family map. · CHEMBL1201516 · CID 16134956 | |
| Orforglipronorforglipron | Drug | CC1=C(C(=O)N2CCCC2)C(=NN1c3ccc(C(=O)O)cc3)… | GLP-1 incretin pharmacophore | 8% | clinical · GLP-1 · oral · small-molecule · Oral non-peptide small-molecule GLP-1RA — modality bridge like Lipfendra in PCSK9. · CID 166024334 | |
| Retatrutide (LY3437943)retatrutide | Drug | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | Tirzepatide (Mounjaro / Zepbound) | 52% | clinical · GLP-1 · GIP · glucagon · triple-agonist · Clinical-stage candidate. Retatrutide (LY3437943) in this family map. | |
| Semaglutide (Ozempic / Wegovy / Rybelsus)semaglutide | Drug | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | GLP-1 incretin pharmacophore | 60% | approved · GLP-1 · peptide · obesity · oral-tablet · Weekly injectable and oral tablet (Rybelsus) GLP-1RA — metabolic/obesity cornerstone. · CHEMBL3707239 · CID 56843331 | |
| Survodutide (BI 456906)survodutide | Drug | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | Liraglutide (Victoza / Saxenda) | 68% | clinical · GLP-1 · glucagon · dual-agonist · Clinical-stage candidate. Survodutide (BI 456906) in this family map. | |
| Tirzepatide (Mounjaro / Zepbound)tirzepatide | Drug | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | Semaglutide (Ozempic / Wegovy / Rybelsus) | 51% | approved · GLP-1 · GIP · dual-agonist · obesity · Dual GIP/GLP-1 receptor agonist — next-wave incretin after mono GLP-1RAs. · CID 156588855 | |
| Fatty-acid acylated GLP-1 SAR analogglp1-sar-fatty-acid | Derivative | N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)… | Semaglutide (Ozempic / Wegovy / Rybelsus) | 72% | SAR · GLP-1 · acylation · SAR exploration node. Derived analog of parent node in GLP-1 / incretin agonist series. |
중심 core chemical에서 바깥 링으로 파생·drug·payload가 퍼지고, 점선·주황 chord는 drug 간 연결(spider web)입니다.
노드를 드래그해 배치를 조정하고, 클릭하면 2D 구조식이 표시됩니다.